TJ004309 is a novel, humanized antibody
against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is highly immunosuppressive.
TJD5, a novel, differentiated humanized antibody
against CD73, is from I-Mab's proprietary discovery pipeline being co-developed through a corporate collaboration between TRACON and I-Mab signed in November 2018.
Some of the core R&D team members had track record of successfully developing two types of humanized antibody
targeted therapeutic drugs which have obtained NMPA approval, as well as several awards, including the National Intellectual Property Gold Award, the National Technological Invention Award and the National Science & Technology Advancement Award.
Under the terms of the agreement, Transcenta will be responsible for the overall preclinical/clinical development, regulatory filing and manufacture of these biologic therapeutics in Greater China, including the phase 2-completed Blosozumab, a humanized antibody
TREATMENT with pembrolizumab, a humanized antibody
used in cancer immunotherapy, may affect pigmentation of some benign skin lesions, according to a case study
Certolizumab pegol is a humanized antibody
Fab fragment, designed by engrafting the mouse complementarity determining region (CDR) into a human IgG4 k Fab framework, and it has a polyethylene glycol (PEG) molecule attached that prolongs the half-life in the circulation; the construct is expressed in bacteria and therefore it lacks glycosylation.
Milatuzumab is a new humanized antibody
which targets tumors with CD74 antigen, expressed on monocytes, macrophages, and B cells but not on T cells .
Species-specific Humanized antibody
really can minimize side effects and allergic reactions but has a long R&D time.
Affinity maturation by molecular modeling increased the affinity of this humanized antibody
to three folds higher than that of the murine antibody.
A humanized antibody
In phase III trials Hoffman La Roche, that binds to a for MS Ltd.) molecule on the surface of select B cells and depletes them from the body Daclizumab High A humanized antibody
In phase III trials Yield Process (DAC that suppresses for MS HYP, Biogen Idec) T cells by blocking signals from an immune messenger protein Lemtrada[TM] A humanized antibody
Phase III trials (alemtuzumab, Sanofi that targets a showed benefit; Aventis) protein on both T company plans to and B cells to shut seek regulatory down cell activity approval from FDA in the first quarter of 2012 BG-12 (dimethyl A chemical compound Phase III trials fumarate, Biogen that promotes cells showed benefit; Idec) that can regulate the company has applied immune response to the FDA for approval for MS.
-- Gevokizumab (XOMA 052), a humanized antibody
that binds to the inflammatory cytokine interleukin-1 beta, or IL-1 beta.